Alkermes plc (NASDAQ: ALKS) today announced that data on three of the company’s clinical programs are scheduled to be presented at two upcoming major medical meetings this week. At the Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec. 2-6, 2012, Alkermes will present pharmacokinetic data on ALKS 9070, a new chemical entity currently in phase 3 development for the treatment of schizophrenia. Results will be shown from a clinical trial supporting the once-monthly dosing regimen for this novel injectable agent. Also at that meeting, positive results will be presented from a phase 1/2 study of ALKS 5461, Alkermes’ novel drug candidate for major depressive disorder (MDD), in patients who have an inadequate response to standard therapies for clinical depression. Data relating to the potential use of ALKS 5461 in the treatment of cocaine dependence will also be presented.
At the American Academy of Addiction Psychiatry (AAAP) Annual Meeting in Aventura, Fla., Dec. 6-9, 2012, new data on the clinical and pharmacoeconomic benefits of naltrexone for extended-release injectable suspension (XR-NTX) will be presented. XR-NTX is marketed by Alkermes as VIVITROL ® and is approved in the U.S. for the treatment of alcohol dependence and the prevention of relapse to opioid dependence following opioid detoxification.
Key presentations for these two medical meetings include:
ACNP Monday, Dec. 3, 2012, at 3:00 p.m. ESTThe oral presentation, “New Clinical Research in Opioid Modulation Indicates Novel Utility in Treating Resistant Depression” will be given by Elliot Ehrich, M.D., Alkermes, Inc., during a mini-panel session entitled, “Renaissance in Opioid Biology: From Preclinical Concepts to Clinical Practice.”Wednesday, Dec. 5, 2012, at 5:30 p.m. ESTPoster 18: “ALKS 5461, a Novel Opioid Receptor Modulator, Reduces the Subjective Effects of Cocaine and was Safe and Well Tolerated During Concurrent Cocaine Administration” will be presented by Ryan Turncliff, Ph.D., Alkermes, Inc. Poster 173: “ALKS 5461, a Novel Opioid Receptor Modulator, Normalizes Human EEG Responses in an Auditory Oddball Task After Cocaine Administration as Indicated by a Novel Brain Network Activation Analysis” will be presented by Edward Sellers, M.D., Ph.D., President and Principal, DL Global Partners Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts